Visual Acuity after Retinal Gene Therapy for Choroideremia
Thomas L. Edwards(University of Oxford), Jasleen K. Jolly(University of Oxford), Markus Groppe(University of Oxford), Alun R. Barnard(University of Oxford), Charles L. Cottriall(Oxford University Hospitals NHS Trust), Tanya Tolmachova(Imperial College London), Graeme C. Black(University of Manchester), Andrew R. Webster(Moorfields Eye Hospital NHS Foundation Trust), Andrew Lotery(University of Southampton), Graham E. Holder(Moorfields Eye Hospital NHS Foundation Trust), Kanmin Xue(University of Oxford), Susan M. Downes(University of Oxford), Matthew P. Simunovic(University of Oxford), Miguel C. Seabra(Imperial College London), Robert E. MacLaren(University of Oxford)
Cited by 193Open Access
Abstract
To the Editor: Two recent clinical reports of retinal gene therapy with adeno-associated virus (AAV) vectors in patients with Leber's congenital amaurosis showed initial gains in visual function that subsequently declined.(1),(2) We previously reported early improvement in visual acuity in two of six patients who received retinal gene therapy in one eye (the study eye) to treat choroideremia,(3) a disease that is characterized by atrophy of the choriocapillaris and retinal pigment epithelium and involves vision loss that leads to blindness. Choroideremia is caused by loss-of-function mutations in the gene CHM. We delivered nonmutated CHM in an AAV vector (AAV.REP1) . . .
Related Papers
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Samuel G. Jacobson, Artur V. Cideciyan, Alejandro J. Román et al.|New England Journal of Medicine|2015|375